A Long-Term Follow-Up Study For Previously Treated With KYV-101 (KYSA-4)

Overview

About this study

The purpose of this study is to evaluate long-term safety following treatment with KYV-101.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Provided informed consent for the LTFU study

  • Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol

Exclusion Criteria:

  • Not applicable.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/21/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Anastasia Zekeridou, M.D., Ph.D.

Contact us for the latest status

Contact information:

Anastasia Zekeridou

5072939597

zekeridou.anastasia@mayo.edu

More information

Publications

Publications are currently not available